URGN Stock Analysis: Buy, Sell, or Hold?
URGN - UroGen Pharma Ltd. Ordinary Shares
$41.40
0.85 (2.10%)
▲
5d:
+0.12%
30d:
-6.8%
90d:
+10.67%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When URGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: URGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: URGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$84.18
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$52.27
20.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: URGN is currently trading at $41.40, which is considered oversold relative to its 30-day fair value range of $41.99 to $45.45. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.8) compared to its historical average (21.5). Remarkably, the market is currently pricing in an annual earnings decline of 11.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, URGN is in a strong uptrend. Immediate support is located at $39.72, while resistance sits at $44.08.
Market Sentiment: URGN scores 64/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $60.00 (+44.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, URGN is in a strong uptrend. Immediate support is located at $39.72, while resistance sits at $44.08.
Market Sentiment: URGN scores 64/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $60.00 (+44.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$41.99 -
$45.45
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
Protect Your Profits
Holding URGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (64/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 44.9% below Wall St target ($60.00)
- CAUTION: Bottoming setup, but lagging the sector by 22% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$41.99 -
$45.45
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$39.72
Resistance Level
$44.08
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.82
Wall Street Target
$60.00
(+44.9%)
Revenue Growth (YoY)
199.2%
Profit Margin
-51.7%
Valuation Discount vs History
-11.6% cheaper
PE vs Historical
14.8 vs 21.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.6%
(market-implied from PE analysis)
1-Year Target
$37.26
(-10%)
2-Year Target
$33.53
(-19%)
3-Year Target
$30.18
(-27%)
3-Yr Target (if PE normalizes)
(PE: 15→22)
$43.80
(+6%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.8 to 21.5
Stabilization Target:
$60.08
(+45.1%)
PE Expansion Potential:
+45.1%
Share & Embed Analysis
Last updated: October 03, 2026 5:14 AM ET
Data refreshes hourly during market hours. Next update: 6:14 AM
Data refreshes hourly during market hours. Next update: 6:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is URGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$21 | 50 HOLD |
Advanced URGN Option Strategies
Professional options setups generated by AI based on today's URGN price and gamma walls.
